The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia

[1] Fischer K(2016)Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial Blood 127 208-215

[2] Bahlo J(2020)Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG) Hemasphere 4 e336-42

[3] Fink AM(2013)Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 32-1007

[4] Kutsch N(2014)Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 997-1363

[5] Bahlo J(2019)Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Am J Hematol 94 1353-1700

[6] Robrecht S(2013)BH3 mimetics: status of the field and new developments Mol Cancer Ther 12 1691-1120

[7] Byrd JC(2018)Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia N Engl J Med 378 1107-1980

[8] Furman RR(2018)Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial J Clin Oncol 36 1973-75

[9] Coutre SE(2018)Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial Lancet Oncol 19 65-1056

[10] Furman RR(2017)Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients Ann Oncol 28 1050-2437

[1] Fischer K(2016)Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial Blood 127 208-215

[2] Bahlo J(2020)Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG) Hemasphere 4 e336-42

[3] Fink AM(2013)Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 32-1007

[4] Kutsch N(2014)Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 997-1363

[5] Bahlo J(2019)Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Am J Hematol 94 1353-1700

[6] Robrecht S(2013)BH3 mimetics: status of the field and new developments Mol Cancer Ther 12 1691-1120

[7] Byrd JC(2018)Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia N Engl J Med 378 1107-1980

[8] Furman RR(2018)Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial J Clin Oncol 36 1973-75

[9] Coutre SE(2018)Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial Lancet Oncol 19 65-1056

[10] Furman RR(2017)Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients Ann Oncol 28 1050-2437